VLA1553 vaccination induces sustained neutralizing antibodies in Brazilian adolescents against chikungunya virus

This study was a randomized, placebo-controlled, phase 3 trial conducted in Brazil. The population consisted of 754 generally healthy adolescents aged 12 to 17 years. Participants were randomized to receive either a single intramuscular dose of VLA1553 or placebo. The primary outcome was the proportion of baseline seronegative participants with chikungunya virus neutralizing antibody levels assessed by a serum dilution achieving a 50% plaque reduction in a micro plaque reduction neutralisation test with a titre of 150 or more. Safety and immunogenicity were evaluated as secondary outcomes over a follow-up period of 12 months.

The primary outcome results demonstrated high immunogenicity. At 28 days after vaccination, 248 of 251 participants (98.8%) in the VLA1553 group achieved seroprotective chikungunya virus neutralizing antibody levels. The 95% confidence interval for this proportion was 96.5% to 99.8%. In the placebo group, the proportion of participants achieving these levels was not explicitly detailed in the provided results, but the direction of the effect was induced by VLA1553.

Immunogenicity was sustained over the long term. At 12 months post-vaccination, 232 of 236 participants (98.3%) maintained seroprotective chikungunya virus neutralizing antibody levels. The 95% confidence interval for this sustained response was 96.7% to 99.5%. This indicates that the vaccine induced a durable immune response in the vast majority of the adolescent population studied.

Safety and tolerability findings were mixed regarding frequency but reassuring regarding severity. The frequency of related adverse events was higher in the VLA1553 group compared to the placebo group. Specifically, 352 (70%) of 502 participants in the VLA1553 group experienced related adverse events, versus 122 (48%) of 252 participants in the placebo group. The p-value for this difference was less than 0.0001. Of the 2082 (97%) of 2155 adverse events reported, the majority were of mild or moderate intensity. The most common adverse events included headache, injection site pain, myalgia, fever, and fatigue.

Regarding serious safety signals, one serious adverse event of high-grade fever was classified as possibly related to VLA1553. No discontinuations were reported in the provided data. The overall tolerability was described as generally well tolerated. Adverse events were classified as related to trial vaccination based on assessment within the trial framework.

The study was funded by the Coalition for Epidemic Preparedness Innovations and EU Horizon 2020. The data support the use of VLA1553 for the prevention of disease caused by the chikungunya virus among adolescents and in endemic regions. While the trial is complete and the results are robust, the specific comparison to prior landmark studies in this therapeutic area is not detailed in the provided text, so direct historical comparisons cannot be made here. The study design was rigorous, but the observational nature of adverse event reporting in the broader context of chikungunya epidemiology remains a consideration.

Key methodological limitations were not explicitly listed in the provided JSON, though the reliance on self-reported or trial-assessed adverse events is standard. Potential biases related to the assessment of causality for adverse events exist, as events were classified as related based on trial assessment. Questions remain unanswered regarding the long-term durability of protection beyond 12 months and the efficacy of the vaccine in adolescents with pre-existing immunity or in non-endemic settings. The study population was restricted to generally healthy adolescents, limiting generalizability to older adults or those with comorbidities.

Clinicians should consider VLA1553 for preventing chikungunya virus disease in adolescents in endemic regions. The high rate of seroprotection and sustained response suggests strong efficacy. However, the increased frequency of mild to moderate adverse events, particularly headache, injection site pain, and fever, must be communicated to patients and guardians. The single serious adverse event of high-grade fever warrants monitoring, though it was classified as possibly related. Practice decisions should weigh the high immunogenicity against the transient nature of the reported adverse events.

In conclusion, this phase 3 trial provides strong evidence for the immunogenicity and safety profile of VLA1553 in adolescents. The 98.8% response rate at 28 days and 98.3% at 12 months are compelling. The safety profile, characterized by mild to moderate events, is consistent with other viral vaccines. Further research is needed to evaluate efficacy in diverse populations and to monitor long-term safety. The data support the potential role of this vaccine in public health strategies for chikungunya prevention.